Verastem Oncology Reports Second Quarter 2023 Financial Resu

Presented Positive Results from Part A of RAMP 201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) at American Society of Clinical Oncology MeetingEstablished Design for RAMP 301 Phase 3 Confirmatory Trial of Avutometinib and Defactinib in Recurrent LGSOCStrengthened Balance...

Related Keywords

United States , American , Dan Calkins , Karin Tollefson , Dan Paterson , Robert Gagnon , Brian Stuglik , Elisa Buffington , Nate Liabraaten , Company Board Of Directors , Raf And Mek Program , Commercialization Committee , American Society Of Clinical Oncology Meeting , Corporate Communications , Company Phase , European Network Of Gynaecological Oncological Trial , Exchange Commission , Drug Administration , Chugai Pharmaceutical Co Ltd , Pancreatic Cancer Action Network Pan , Company Cash , Amgen , Foundation Inc , Presented Positive Results , Recurrent Low Grade Serous Ovarian Cancer , American Society , Clinical Oncology , Balance Sheet , Including Receipt , Gross Proceeds , Bringing Company Cash , Cash Equivalents , Verastem Oncology , Chief Executive Officer , Grade Serous Ovarian Cancer , European Network , Gynaecological Oncological Trial , Clinical Oncology Meeting , Breakthrough Therapy Designation , Pancreatic Cancer Action Network , Chief Operating Officer , Senior Vice President , Global Medical Affairs , Breakthrough Therapy , Annual Report , Consolidated Statements ,